SEC Comment Letter 0000000000-24-003169 to HilleVax, Inc. (HLVX) (CIK 0001888012)
HilleVax, Inc. (HLVX) (CIK 0001888012)
Date: March 22, 2024 · CIK: 0001888012 · Accession: 0000000000-24-003169
AI Filing Summary & Sentiment
File numbers found in text: 333-278110
Letter
United States securities and exchange commission logo March 22, 2024 Robert Hershberg Chief Executive Officer HilleVax, Inc. 321 Harrison Avenue Boston, MA 02118 Re:HilleVax, Inc. Registration Statement on Form S-3 Filed March 20, 2024 File No. 333-278110 Dear Robert Hershberg: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cheston Larson
Show Raw Text
United States securities and exchange commission logo
March 22, 2024
Robert Hershberg
Chief Executive Officer
HilleVax, Inc.
321 Harrison Avenue
Boston, MA 02118
Re:HilleVax, Inc.
Registration Statement on Form S-3
Filed March 20, 2024
File No. 333-278110
Dear Robert Hershberg:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Cheston Larson